This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

This study has been completed.
Quintiles, Inc.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: December 9, 2009
Last updated: July 26, 2012
Last verified: March 2010
The main purpose of this study is to assess the safety, tolerability and PK of AZD9742 after single IV doses.

Condition Intervention Phase
Healthy Drug: AZD9742 Drug: Placebo to match AZD9742 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase-1, Single Center, Double Blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 After Single Ascending Doses in Healthy Male and Female Subjects

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety and tolerability of AZD9742 will be assessed by incidence and severity of AE's, abnormalities in vital signs, ECG's, telemetry, clinical laboratory assessments, physical exams and withdrawals [ Time Frame: Assessments taken at Visit 1 (enrollment), defined timepoints pre-dose and post-dose during Visit 2 (residential period) and at Visit 3 (follow up). Volunteers will be monitored througout the study from Visit 1 through Visit 3 for adverse events. ]

Secondary Outcome Measures:
  • Pharmacokinetic profile: to characterize the pharmacokinetics of AZD9742 in blood and urine [ Time Frame: Samples taken during Visit 2 (residential period) at defined timepoints pre-dose and post-dose. ]

Enrollment: 48
Study Start Date: November 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZD9742 IV Infusion
Drug: AZD9742
Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
Placebo Comparator: Placebo to AZD9742 IV Infusion
Drug: Placebo to match AZD9742
Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)


Ages Eligible for Study:   23 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of signed and dated, written informed consent prior to any study specific procedures.
  • Clinically normal physical findings and laboratory values as judged by the investigator with normal ECG.
  • Healthy male and female volunteers. Females must be of non childbearing potential.

Exclusion Criteria:

  • Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 4 weeks of the first administration of the Investigational Product
  • History of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01030224

United States, Kansas
Research Site
Overland Park, Kansas, United States
Sponsors and Collaborators
Quintiles, Inc.
Principal Investigator: Dr. Ralph A Schutz Quintiles, Inc.
  More Information

Responsible Party: AstraZeneca Identifier: NCT01030224     History of Changes
Other Study ID Numbers: D2690C00001
Study First Received: December 9, 2009
Last Updated: July 26, 2012

Keywords provided by AstraZeneca:
Healthy volunteer
First time in human processed this record on September 21, 2017